Navigation Links
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
Date:4/16/2008

- Scientific Presentation at the 99th Annual Meeting of the American

Association for Cancer Research (AACR) -

TORONTO, April 16 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced presentations of further preclinical data from its two lead anticancer drugs at the Annual Meeting of the AACR in San Diego, CA, April 12-16, 2008.

The first presentation titled, "Preclinical development of LOR-253, a novel anticancer drug candidate that functions by modulating intracellular labile zinc homeostasis leading to cell cycle arrest," will be presented on April 16, 2008.

In this presentation, Lorus provided data on the preclinical development of LOR-253 (formerly known as LT-253), the Company's lead anticancer small molecule, with a novel cellular target. In animal studies, LOR-253 showed a favorable pharmacokinetic profile following intravenous dosing. A key finding of the study was the tissue distribution of LOR-253, where the drug was detected in tumor tissues in animal models, with significant affinity for lung and colon tissues. These results strongly support the potential treatment of these cancers with LOR-253, which has shown selective and potent anticancer activity in animal models of non-small cell lung cancer and colon cancer.

LOR-253 is currently in IND-enabling GLP toxicology studies, which are to be completed by mid-2008. Planning of a Phase I clinical trial in cancer indications for LOR-253 is in progress.

The second presentation, presented on April 13, 2008 titled, "GTI-2040 displays cooperative anti-tumor activity, when combined with chemotherapeutics and immunotherapeutics against human renal carcinoma xenografts".

This study reported preclinical results from combination therapies with
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... "Global N-acetylcysteine Industry Report 2014" report to ... Industry Report 2014 is a professional and in-depth ... N-acetylcysteine industry. The report provides a ... applications and industry chain structure. The N-acetylcysteine market ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 2
... NEW YORK, Nov. 9, 2010 Reportlinker.com announces that ... catalogue: Biomarkers - technologies,markets and ... Summary This report follows ... that can be objectively measured and evaluated as an ...
... NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" or ... U.S. and China, today announced that NeoStem,s Chairman and CEO, ... at Moves Magazine,s 2010 Power Women Awards Dinner & Ceremony ... Street, New York City. This event marks ...
... Nov. 9, 2010 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Biology Technology:Reportlinker Adds Biomarkers - Technologies, Markets And Companies 2Reportlinker Adds Biomarkers - Technologies, Markets And Companies 3Reportlinker Adds Biomarkers - Technologies, Markets And Companies 4Reportlinker Adds Biomarkers - Technologies, Markets And Companies 5Reportlinker Adds Biomarkers - Technologies, Markets And Companies 6Reportlinker Adds Biomarkers - Technologies, Markets And Companies 7Reportlinker Adds Biomarkers - Technologies, Markets And Companies 8Reportlinker Adds Biomarkers - Technologies, Markets And Companies 9Reportlinker Adds Biomarkers - Technologies, Markets And Companies 10Reportlinker Adds Biomarkers - Technologies, Markets And Companies 11Reportlinker Adds Biomarkers - Technologies, Markets And Companies 12Reportlinker Adds Biomarkers - Technologies, Markets And Companies 13Reportlinker Adds Biomarkers - Technologies, Markets And Companies 14Reportlinker Adds Biomarkers - Technologies, Markets And Companies 15Reportlinker Adds Biomarkers - Technologies, Markets And Companies 16Reportlinker Adds Biomarkers - Technologies, Markets And Companies 17Reportlinker Adds Biomarkers - Technologies, Markets And Companies 18Reportlinker Adds Biomarkers - Technologies, Markets And Companies 19Reportlinker Adds Biomarkers - Technologies, Markets And Companies 20NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards 2China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 2China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 3China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 4China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 5China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 6China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 7China Biologic Products Schedules Conference Call to Discuss Third Quarter 2010 Results 8
(Date:9/18/2014)... and ethnic groups describe losing eyesight as potentially ... more so than other conditions including: loss of ... 49% of non-Hispanic whites, 43% of Asians and ... ailment is the worst that could happen to ... AIDS/HIV. Hispanics and Asians ranked cancer first ...
(Date:9/18/2014)... Elsevier, a world-leading provider of scientific, technical and ... Research Management Society (ARMS), recognized the academic research ... Scopus Young Researcher of the Year Awards. , ... National Convention Centre and in conjunction with the ... representing Australia,s and New Zealand,s scientific community. Guest ...
(Date:9/18/2014)... protective tentacles of host anemones, but new research shows ... across the open ocean. Although the process of long-distance ... the first time that the high level exchange of ... Steve Simpson, Senior Lecturer in Marine Biology and Global ... the Australian Research Council Centre of Excellence for Coral ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... diagnostics could be minutes particles of rust, iron oxide, ... silicon dioxide. These magnetic nanoparticles, a mere 29 to ... trap antibodies to the virus that causes cervical cancer ... According to scientists in Vietnam, it is relatively ...
... Scripps Research Institute scientists have converted adult skin ... to first go through the laborious process of generating ... lead to new treatments for a range of diseases ... heart disease, Parkinson,s, and Alzheimer,s disease. The work ...
... the dozens of antibiotics that followed it, streptococcus bacteria ... world. The reason: the superb evolutionary skills of this ... landmark paper published this week in Science , ... used full genome sequencing to identify the precise steps ...
Cached Biology News:Detecting lethal diseases with rust and sand 2Scripps Research scientists convert skin cells to beating heart cells 2Scripps Research scientists convert skin cells to beating heart cells 3New research traces evolutionary path of multidrug-resistant strep bacteria 2New research traces evolutionary path of multidrug-resistant strep bacteria 3
Sheep Serum US Origin...
Human LAIR2 Biotinylated Affinity Purified PAb...
... Lacks the mycobacteria found in Complete Freund's Adjuvant ... Incomplete, Freund's Adjuvant is used ... used to produce water-in-oil emulsions of immunogens. ... long-lasting antibody responses which can be attributed to ...
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: